Aeterna Zentaris Inc.
Formerly Aeterna Laboratories Inc.
Aeterna Zentaris Inc. is listed today as COSCIENS Biopharma Inc.: market value, financials and filings are on its company page.
Funding rounds
0 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Feb 2020 | $5 M | Private placement after listing | $2 to $10 million | options | SEC | |
| Sep 2019 | $5 M | Private placement after listing | $2 to $10 million | options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company COSCIENS Biopharma Inc., its revenue in fiscal 2025 came from these product and service lines: Active ingredients $7.04 million (94%), Biopharmaceutical $460,000 (6%).
Annual report (SEC XBRL) · Dec 2025
Aeterna Zentaris Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2020).
SEC Form D · Mar 2020
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Mar 2020
Products and services#
No products or services of Aeterna Zentaris Inc. are on record.
Investors#
No investor of Aeterna Zentaris Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Klaus Paulini | Executive officer | Mar 2020 |
| Leslie Auld | Executive officer | Mar 2020 |
| Nicola Ammer | Executive officer | Mar 2020 |
| Klaus V. Paulini | Executive officer | Oct 2019 |
| Leslie V. Auld | Executive officer | Oct 2019 |
| Michael V. Ward | Executive officer | Oct 2019 |
| Nicola V. Ammer | Executive officer | Oct 2019 |
| Brent Norton | Director | Mar 2020 |
| Carolyn Egbert | Director | Mar 2020 |
| Gerard Limoges | Director | Mar 2020 |
| Gilles Gagnon | Director | Mar 2020 |
| Klaus Paulini | Director | Mar 2020 |
| Robin Smith Hoke | Director | Mar 2020 |
| Brent V. Norton | Director | Oct 2019 |
| Carolyn V. Egbert | Director | Oct 2019 |
| Gerard V. Limoges | Director | Oct 2019 |
| Robin V. Smith Hoke | Director | Oct 2019 |
Went public since 2017. Its SEC number is that of a company listed on a stock exchange.